Release Date: August 20, 2025
Expiration Date: August 20, 2026
Activity Overview
The management of extensive-stage small cell lung cancer (ES-SCLC) is poised to change substantially with recent practice-changing trial data. Navigating optimal management for patients along the treatment continuum is critical for extending the lives of patients with this form of cancer.
This podcast features a discussion about the current standard of care in terms of molecular testing and management of lung cancer. Led by Rohit Gosain, MD; and Rahul Gosain, MD; this session features a faculty expert in evaluating and treating cancers.
Target Audience
This educational activity is intended for medical oncologists, nurse practitioners, physician assistants, and oncology nurses who manage patients with SCLC.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Analyze recent clinical trial data on new maintenance strategies and treatment options for relapsed/refractory ES-SCLC
- Recognize the unmet clinical needs in SCLC and potential opportunities to improve patient outcomes
Rahul Gosain, MD, MBA
Assistant Professor of Clinical Medicine
Medical Director, Wilmot Cancer Institute at Webster
Director, Wilmot Cancer Institute Regional Infusion Services
Wilmot Cancer Institute–Webster
University of Rochester Medicine
Rochester, NY
Disclosures: Consultancy/Advisory: AstraZeneca, Gilead, Janssen Oncology; Honorarium: Cor2ed, Integrity CE, Oncology News Central, SignifyMD
Rohit Gosain, MD
Assistant Professor of Clinical Medicine
University of New York at Buffalo
Director of Roswell Park Care Network Southtowns
Roswell Park Comprehensive Cancer Center
Buffalo, NY
Disclosures: Consultancy/Advisory: Eisai; Honorarium: Cor2ed, Integrity CE, Oncology News Central, SignifyMD
Hossein Borghaei, DO, MS
Professor, Department of Hematology/Oncology
Chief, Division of Thoracic Medical Oncology
Fox Chase Cancer Center
Philadelphia, PA
Disclosures: Advisory Board/Consultant: AbbVie, Amgen, Astellas, AstraZeneca, Axiom, Bayer, BeiGene, BerGenBio, BioNTech, BMS, Boehringer Ingelheim, Daiichi, EMD-Serono, Genentech, Genmab, Gilead, Grid Therapeutics, Guardant, IO Biotech, iTEO, Janssen, Jazz, Lilly, Merck, Mirati, Natera, Novartis, Novocure, Oncocyte, Pfizer, PharmaMar, Puma, RAPT, Regeneron, Summit, Systimmune, Takeda; Grant/Research Funding: Amgen, BMS, Lilly; Honoraria: Amgen, Daiichi, Janssen, Jazz, Pfizer, Regeneron; Ownership Interests in Privately Held Companies: Inspirna (formerly Rgenix; stock options), Nucleai (stock options), Sonnet Bio (stock options); Travel: Amgen, BMS, EMD-Serono, Genentech, Incyte, Jazz, Lilly, Merck, Mirati, Novartis, Regeneron, Servier, SpringWorks, Takeda, University of Pennsylvania: CAR T program
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.